EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSOMYG00000031572
Gene Symbol: NR3C1
1 Cross references
198 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSOMYG00000022763
Gene Symbol: NR3C1
2 Cross references
200 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSOMYG00000042542
Gene Symbol: NR3C1
1 Cross references
200 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSOMYG00000040062
Gene Symbol: NOD2
2 Cross references
166 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSOMYG00000071445
Gene Symbol: OPRL1
1 Cross references
184 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSOMYG00000010927
Gene Symbol: OPRL1
1 Cross references
185 Possible Orthologues:

Opioid Receptor, Delta 1b

Ensembl ID : ENSOMYG00000002011
Gene Symbol: OPRD1B
1 Cross references
128 Possible Orthologues:

Opioid Receptor, Kappa 1

Ensembl ID : ENSOMYG00000007897
Gene Symbol: OPRK1
1 Cross references
197 Possible Orthologues:

Opioid Receptor, Mu 1

Ensembl ID : ENSOMYG00000033340
Gene Symbol: OPRM1
1 Cross references
208 Possible Orthologues:

Opioid Receptor, Mu 1

Ensembl ID : ENSOMYG00000041891
Gene Symbol: OPRM1
2 Cross references
207 Possible Orthologues:

Oxytocin Receptor A

Ensembl ID : ENSOMYG00000047796
Gene Symbol: OXTRA
1 Cross references
185 Possible Orthologues:

Oxytocin Receptor A

Ensembl ID : ENSOMYG00000026475
Gene Symbol: OXTRA
1 Cross references
185 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).